Trial Profile
Phase 2 Proof-of-Concept Trial Testing the PARP Inhibitor Niraparib in Patients With Pancreatic Cancer Harboring Deficiencies in Homologous Recombination DNA Repair
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Feb 2024
Price :
$35
*
At a glance
- Drugs Niraparib (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Proof of concept; Therapeutic Use
- 10 Feb 2024 Planned primary completion date changed from 30 Mar 2023 to 30 Sep 2024.
- 25 Oct 2023 Status changed from recruiting to active, no longer recruiting.
- 09 Jan 2023 Planned primary completion date changed from 30 Nov 2022 to 30 Mar 2023.